Related Experiment Video

Updated: Jul 5, 2026

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
06:50

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

[Dyslipidemias in type 1 diabetes: a current approach]

Alessandra S de Mattos Matheus1, Roberta Arnoldi Cobas, Marília B Gomes

  • 1Departamento de Medicina Interna, Faculdade de Ciências Médicas, Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro RJ, Brasil.

Arquivos Brasileiros De Endocrinologia E Metabologia
|April 29, 2008
PubMed

Insights

Cardiovascular disease is a major risk for type 1 diabetes mellitus (T1DM) patients. Early diagnosis and treatment of dyslipidemia are crucial for managing T1DM cardiovascular risks.

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Disorders

Context:

  • Intensive glycemic control in type 1 diabetes mellitus (T1DM) increases cardiovascular disease (CVD) risk, the leading cause of mortality.
  • Dyslipidemia is a significant risk factor for microvascular and macrovascular complications in T1DM.
  • Current guidelines for coronary artery disease prevention primarily focus on type 2 diabetes mellitus, neglecting T1DM.

Purpose:

  • To highlight the importance of diagnosing dyslipidemia in T1DM patients.
  • To advocate for early and appropriate treatment of dyslipidemia in T1DM.
  • To reduce the atherogenic lipid profile and improve treatment outcomes in T1DM.

Summary:

  • This study emphasizes the critical need for early dyslipidemia diagnosis in type 1 diabetes mellitus (T1DM) patients.
  • It addresses the lack of attention to T1DM in cardiovascular disease prevention guidelines.
  • The research advocates for timely therapeutic interventions to manage dyslipidemia and mitigate cardiovascular risks.

Impact:

  • Establishes the significance of identifying and treating dyslipidemia in T1DM.
  • Aims to reduce cardiovascular mortality in T1DM patients.
  • Provides a foundation for developing targeted T1DM cardiovascular prevention strategies.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...